Want to see TSE:PHRM full AI Analyst Report?
Top Page
PharmaTher Holdings Ltd
(PHRM)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$0.07
▲(8.33% Upside)
Action:Reiterated
Date:10/06/26
The score is held back primarily by weak financial fundamentals typical of a pre-revenue biotech (ongoing losses/cash burn and sharply reduced equity), despite the benefit of having no debt and improving loss/cash-burn trends. Technicals are comparatively supportive with price above major short/medium moving averages and positive momentum, while valuation is constrained by negative earnings and no dividend.
Positive Factors
Debt-free balance sheet
The absence of total debt reduces refinancing pressure and interest-related demands on limited resources. This gives management greater flexibility to direct available capital toward development programs and helps the company withstand funding or operating setbacks without adding leverage.
Negative Factors
No recurring revenue base
The absence of reported revenue means the company has not yet demonstrated commercial demand or an operating revenue engine. Funding therefore depends on development progress and external capital rather than internally generated sales, making the business model materially less resilient over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of total debt reduces refinancing pressure and interest-related demands on limited resources. This gives management greater flexibility to direct available capital toward development programs and helps the company withstand funding or operating setbacks without adding leverage.
Read all positive factors
PharmaTher Holdings Ltd (PHRM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.46M
Dividend YieldN/A
Average Volume (3M)46.03K
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue GrowthN/A
EPS Growth61.05%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume81,992
30 Day Avg. Volume46,027
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)8.91
Price to Sales (P/S)0.00
P/FCF Ratio-11.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)C$83.60M
PharmaTher Holdings Ltd Business Overview & Revenue Model
Company Description
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration tec...
PharmaTher Holdings Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | May 2026 | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -711.00 | -1.42K | -1.78K |
| EBITDA | -845.95K | -1.52M | -3.04M | -3.96M | -3.96M |
| Net Income | -610.44K | -1.53M | -3.12M | -6.42M | -4.01M |
Balance Sheet | |||||
| Total Assets | 1.12M | 1.34M | 2.59M | 6.31M | 12.16M |
| Cash, Cash Equivalents and Short-Term Investments | 921.54K | 1.12M | 2.30M | 6.25M | 12.12M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 509.14K | 366.33K | 252.90K | 892.48K | 330.32K |
| Stockholders Equity | 613.11K | 973.54K | 2.34M | 5.42M | 11.83M |
Cash Flow | |||||
| Free Cash Flow | -485.01K | -1.21M | -3.52M | -3.24M | -3.51M |
| Operating Cash Flow | -485.01K | -1.21M | -3.52M | -3.24M | -3.51M |
| Investing Cash Flow | 0.00 | 0.00 | -300.00K | 0.00 | 0.00 |
| Financing Cash Flow | 250.00K | 0.00 | 35.00K | 0.00 | 9.89M |
PharmaTher Holdings Ltd Technical Analysis
Positive
0.06
Price Trends
0.06
Positive
0.06
Positive
0.07
Negative
Market Momentum
<0.01
Negative
57.60
Neutral
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRM, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.60 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PHRM.
PharmaTher Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | C$9.57M | -0.52 | -48.52% | ― | -13.00% | 75.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$5.46M | -9.09 | -98.98% | ― | ― | 61.05% | |
46 Neutral | C$7.25M | -4.31 | 39.05% | ― | ― | 25.70% | |
41 Neutral | C$6.15M | -2.05 | 273.53% | ― | ― | ― | |
40 Underperform | C$157.59M | -11.59 | 34.90% | ― | ― | -266.67% | |
29 Underperform | C$2.04M | -0.91 | 69.89% | ― | ― | ― |
* Healthcare Sector Average
TSE:PHRM
PharmaTher Holdings Ltd
0.06
-0.10
-62.50%
TSE:CSCI
COSCIENS Biopharma
9.60
-1.35
-12.33%
TSE:KNE
Kane Biotech
0.03
-0.01
-25.00%
TSE:BETR
BetterLife Pharma
0.26
0.19
292.31%
TSE:BIOV
BioVaxys Technology
0.07
-0.20
-74.07%
TSE:MRVL
Marvel Biosciences Corp
0.12
-0.11
-48.89%
PharmaTher Holdings Ltd Corporate Events
Business Operations and StrategyProduct-Related Announcements
PharmaTher Secures Exclusive North American Rights to Craft Health’s 3D Pharma Printing Platform
Positive
Oct 1, 2026
PharmaTher has signed an exclusive distribution agreement with Singapore-based Craft Health to distribute its CraftMake pharmaceutical 3D printing platform, software, printable formulations and consumables across North America. The deal positions ...
Business Operations and StrategyProduct-Related Announcements
PharmaTher Taps PD Labs as U.S. Hub for 3D-Printed Personalized Medicines
Positive
Aug 18, 2026
PharmaTher has advanced the commercialization of its PERSONALIZ3D platform by selecting PD Labs, a national 503A compounding pharmacy in Texas, as its U.S. Center of Excellence. The move marks completion of the first stage of its three-part plan t...
Business Operations and StrategyProduct-Related Announcements
PharmaTher Unveils PERSONALIZ3D Platform to Merge Telehealth and 3D-Printed Personalized Medicines
Positive
Aug 11, 2026
PharmaTher Holdings has launched PERSONALIZ3D, a personalized medicine platform that integrates telehealth, pharmaceutical 3D printing and pharmacy partnerships to create an end-to-end ecosystem for customized treatments. The system aims to digita...
Business Operations and StrategyDividends
Source Rock Royalties Declares Monthly Dividend and Grants Incentive RSUs
Positive
Jul 16, 2026
Source Rock Royalties Ltd., a Calgary-based oil and gas royalty specialist, concentrates on oil-focused royalty interests across key Canadian basins and leverages niche industry relationships to source both existing and newly created royalties. It...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.